-
SIYU CHEN
Counsel·Shanghai
PROFILE REPRESENTATIVE MATTERS AND CASES OTHER INFORMATION Further Reading
MS. CHEN SPECIALIZES IN M&A, PRIVATE EQUITY INVESTMENT AND GENERAL CORPORATE.
Education
Cornell Law School, LL.M.
East China University of Political Science and Law, LL.B.
Professional Qualification
Admitted to practice in the PRC
Admitted to practice in the State of New York
Professional Background
Ms. Chen joined Fangda Partners in 2016.
PROFILE
REPRESENTATIVE MATTERS AND CASES
- Represented TPG in its pre-IPO investment in a company engaged in medical device manufacturing and a company engaged in medical device R&D
- Represented Blackstone in its acquisition of a company engaged in manufacturing medical packaging tubes
- Represented Centurium Capital and the buyer group in their privatization of China Biologic Products (named “Asia-Pacific Deal of the Year (Equity)”, IFLR Awards, 2022)
- Represented PAG in its investment in Alphamab Oncology
- Represented Hillhouse in its equity investment in a company engaged in gene therapy R&D and manufacturing
- Represented Boyu Capital in its equity investment in Shuidichou and a company engaged in medical device manufacturing and R&D
- Represented Primavera in its equity investment in a company engaged in logistics and transportation
- Represented YF Capital in its equity investment in Livzon Mabpharm
- Represented Partners Group in its acquisition of a company engaged in display prop manufacturing and a company engaged in cross-border logistics transportation
- Represented Nexus Point in its acquisition of a company engaged in international freight forwarding business
- Represented RA Capital in its equity investment in Connect Biopharma, a company engaged in innovative drug R&D
- Represented AstraZeneca-CICC medical fund, CICC Capital, CITIC Capital, WuXi AppTec, CBC Group, Huagai Capital, Highlight Capital, CD Capital, and Shiyu Capital in their equity investments in bio-pharmaceutical enterprises, including companies engaged in medical technology, in medical services, and in new drug and medical device R&D, manufacturing and sales
- Represented Alibaba in its equity investment in Zto Express and in companies engaged in logistics transportation
- Represented Ant Financial in its acquisition of a company engaged in fresh food e-commerce
- Represented Shanghai Highly (Group) in its establishment of a joint venture with Voltas Limited in India
- Represented Enmore Group in its establishment of a joint venture with TP ICAP in China
- Represented New Horizon Health in its listing on the main board of the HKEx
- Represented FOSUN Pharma in its introduction of the COVID-19 vaccine into the PRC, Hong Kong SAR and Macao SAR
